REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced three poster presentations scheduled for the Annual Meeting of the American Society of Clinical Oncology taking place in Atlanta, GA, from June 2 - 6, 2006. Following are details for each embargoed session:
Saturday, June 3, 2006, 8:00 AM - 12:00 PM Abstract #538 Poster presentation: Gene expression profiles in formalin-fixed, paraffin-embedded (FFPE) core biopsies predict docetaxel chemosensitivity. Presenter: Jenny C. Chang, M.D. Sunday, June 4, 2006, 8:00 AM - 12:00 PM Abstract #3518 Poster presentation: Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. Presenter: Michael J. O’Connell, M.D. Tuesday, June 6, 2006, 8:00 AM - 12:00 PM Abstract #6024 Poster presentation: 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) breast cancer: An economic analysis including prognostic and predictive information. Presenter: Leon E. Cosler, Ph.D., R.Ph. About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
Genomic Health, Inc.
CONTACT: Emily Faucette of WeissComm Partners, +1-415-946-1066, forGenomic Health, Inc.; or Brad Cole of Genomic Health, Inc., +1-650-569-2281
Web site: http://www.genomichealth.com//
